Copyright
©The Author(s) 2022.
World J Diabetes. Nov 15, 2022; 13(11): 962-971
Published online Nov 15, 2022. doi: 10.4239/wjd.v13.i11.962
Published online Nov 15, 2022. doi: 10.4239/wjd.v13.i11.962
Defensin | Main cellular source | Action | ||
α-defensin | HNP1 | Neutrophils; monocytes; macrophages; natural killer cells | Increase the healing rate of MRSA-infected wounds[6]; promote hemostasis[7]; r/affect the cardiovascular system[8]; inhibit thrombus formation[9] | Anti-infection and immunoregulation[23] |
HNP2-3 | Anti-tumor activity[10] | |||
HNP4 | Neutrophils | Characterize benign and malignant salivary gland tumors[11] | ||
HD5-6 | Intestinal Paneth cells | Reverse dyslipidemia and improve glucoregulatory capacity[12]; anti-tumor ability[13]; amyloid inhibitor[14] | ||
β-defensin | HBD1 | Epithelial cells; monocytes; macrophages | Anti-tumor activity[15]; potentiate osteoclastogenesis[16] | Induce the secretion of angiogenin[54]; anti-infection and immunoregulation[23] |
HBD2 | Accelerate wound healing[17]; Oncolytic activity[18]; reduce alcoholic liver injury[19] | |||
HBD3 | Accelerate wound healing[20]; induce IL-8 release and apoptosis in airway smooth muscle cells[21] | |||
HBD4 | Epithelial cells | Stimulate/suppress cancer cell proliferation and viability[22] |
Stage | Defensin | Activation |
Inflammation | HNP1-2, HBD1-3[28] | Recruitment of leukocytes |
HNP1-4[29] | Secretion of inflammatory cytokines like IL-8 | |
HBD2-4[32] | Activation of the p38 and ERK1/2 MAPK pathways | |
HNP1, HBD2[35] | Activation of the p42/44 MAPK pathways | |
HBD2, HBD3[36] | Down-regulate the TIR, TRAF-6, NF-κB of TLR signaling pathways | |
HBD3[37] | Induce M2 macrophage differentiation | |
Re-epithelialization | HNP1[43], HBD2-3[42] | Induce keratinocyte migration and proliferation |
HBD1[44] | Protect keratinocytes from apoptosis | |
Collagen synthesis | HNP1[45] | Enhance extracellular matrix deposition |
HBD3[20,37] | Increase the expression of MMP-2, and down-regulate the expression of MMP-9 | |
Fibroplasia | HNP1[45], HBD2[46] | Promote the proliferation and activation of fibroblasts |
Angiogenesis | HNP1[51], HBD2[52], HBD3[53] | Induce VEGF |
HBD1-4[54] | Induce angiogenin | |
HNPs[55] | Inhibit adhesion and migration of endothelial cell | |
Nerve reconstruction | HNP1[40] | Promote the recovery of neurological function |
HBD3[57] | Modulate the expression of nerve elongation factors | |
Antimicrobial activity | HNP1-4, HBD1-4[61] | Exhibit a broad range of antimicrobial properties |
HBD2[60] | Reduce biofilm formation | |
HNP1-3[62] | Neutralize bacterial toxins | |
HNP1, HBD1, HBD3[63] | Show synergy of action with antibiotics |
- Citation: Tan ZX, Tao R, Li SC, Shen BZ, Meng LX, Zhu ZY. Role of defensins in diabetic wound healing. World J Diabetes 2022; 13(11): 962-971
- URL: https://www.wjgnet.com/1948-9358/full/v13/i11/962.htm
- DOI: https://dx.doi.org/10.4239/wjd.v13.i11.962